Literature DB >> 20650515

Time to act: a call for comprehensive responses to HIV in people who use drugs.

Chris Beyrer1, Kasia Malinowska-Sempruch, Adeeba Kamarulzaman, Michel Kazatchkine, Michel Sidibe, Steffanie A Strathdee.   

Abstract

The published work on HIV in people who use drugs shows that the global burden of HIV infection in this group can be reduced. Concerted action by governments, multilateral organisations, health systems, and individuals could lead to enormous benefits for families, communities, and societies. We review the evidence and identify synergies between biomedical science, public health, and human rights. Cost-effective interventions, including needle and syringe exchange programmes, opioid substitution therapy, and expanded access to HIV treatment and care, are supported on public health and human rights grounds; however, only around 10% of people who use drugs worldwide are being reached, and far too many are imprisoned for minor offences or detained without trial. To change this situation will take commitment, advocacy, and political courage to advance the action agenda. Failure to do so will exacerbate the spread of HIV infection, undermine treatment programmes, and continue to expand prison populations with patients in need of care. Copyright 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20650515      PMCID: PMC3682471          DOI: 10.1016/S0140-6736(10)60928-2

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  38 in total

1.  Incarceration and risk for HIV infection among injection drug users in Bangkok.

Authors:  Kachit Choopanya; Don C Des Jarlais; Suphak Vanichseni; Dwip Kitayaporn; Philip A Mock; Suwanee Raktham; Krit Hireanras; William L Heyward; Sathit Sujarita; Timothy D Mastro
Journal:  J Acquir Immune Defic Syndr       Date:  2002-01-01       Impact factor: 3.731

2.  Transition and the HIV risk environment.

Authors:  Tim Rhodes; Milena Simic
Journal:  BMJ       Date:  2005-07-23

Review 3.  HIV in prison in low-income and middle-income countries.

Authors:  Kate Dolan; Ben Kite; Emma Black; Carmen Aceijas; Gerry V Stimson
Journal:  Lancet Infect Dis       Date:  2007-01       Impact factor: 25.071

4.  Antiretroviral adherence and HIV treatment outcomes among HIV/HCV co-infected injection drug users: the role of methadone maintenance therapy.

Authors:  Anita Palepu; Mark W Tyndall; Ruth Joy; Thomas Kerr; Evan Wood; Natasha Press; Robert S Hogg; Julio S G Montaner
Journal:  Drug Alcohol Depend       Date:  2006-03-20       Impact factor: 4.492

Review 5.  Update and overview of practical epidemiologic aspects of HIV/AIDS among injection drug users in the United States.

Authors:  Scott S Santibanez; Richard S Garfein; Andrea Swartzendruber; David W Purcell; Lynn A Paxton; Alan E Greenberg
Journal:  J Urban Health       Date:  2006-01       Impact factor: 3.671

6.  The cost-effectiveness of expanding harm reduction activities for injecting drug users in Odessa, Ukraine.

Authors:  Peter Vickerman; Lilani Kumaranayake; Olga Balakireva; Lorna Guinness; Oksana Artyukh; Tatiana Semikop; Olexander Yaremenko; Charlotte Watts
Journal:  Sex Transm Dis       Date:  2006-10       Impact factor: 2.830

7.  HIV and related risk behavior among men who have sex with men in Zanzibar, Tanzania: results of a behavioral surveillance survey.

Authors:  Mohammed Dahoma; Lisa G Johnston; Abigail Holman; Leigh Ann Miller; Mahmoud Mussa; Asha Othman; Ahmed Khatib; Ramadhan Issa; Carl Kendall; Andrea A Kim
Journal:  AIDS Behav       Date:  2011-01

8.  Directly administered antiretroviral therapy in methadone clinics is associated with improved HIV treatment outcomes, compared with outcomes among concurrent comparison groups.

Authors:  Gregory M Lucas; B Anna Mullen; Paul J Weidle; Shannon Hader; Mary E McCaul; Richard D Moore
Journal:  Clin Infect Dis       Date:  2006-04-28       Impact factor: 9.079

9.  The changing molecular epidemiology of HIV type 1 among northern Thai drug users, 1999 to 2002.

Authors:  Sodsai Tovanabutra; Chris Beyrer; Supachai Sakkhachornphop; Myat Htoo Razak; Gabriela L Ramos; Tassanai Vongchak; Kittipong Rungruengthanakit; Pongpran Saokhieo; Kwanchanok Tejafong; Bohye Kim; Mark De Souza; Merlin L Robb; Deborah L Birx; Jaroon Jittiwutikarn; Vinai Suriyanon; David D Celentano; Francine E McCutchan
Journal:  AIDS Res Hum Retroviruses       Date:  2004-05       Impact factor: 2.205

10.  Uptake and adherence to highly active antiretroviral therapy among HIV-infected people with alcohol and other substance use problems: the impact of substance abuse treatment.

Authors:  Anita Palepu; Nicholas J Horton; Nicole Tibbetts; Seville Meli; Jeffrey H Samet
Journal:  Addiction       Date:  2004-03       Impact factor: 6.526

View more
  73 in total

Review 1.  Meta-analysis of hepatitis C seroconversion in relation to shared syringes and drug preparation equipment.

Authors:  Enrique R Pouget; Holly Hagan; Don C Des Jarlais
Journal:  Addiction       Date:  2012-04-17       Impact factor: 6.526

Review 2.  Response to the AIDS pandemic--a global health model.

Authors:  Peter Piot; Thomas C Quinn
Journal:  N Engl J Med       Date:  2013-06-06       Impact factor: 91.245

3.  Ethical issues in HIV prevention research with people who inject drugs.

Authors:  Jeremy Sugarman; Scott M Rose; David Metzger
Journal:  Clin Trials       Date:  2013-10-14       Impact factor: 2.486

4.  Macrophage endocytic trafficking of antiretroviral nanoparticles.

Authors:  Irena Kadiu; Ari Nowacek; Joellyn McMillan; Howard E Gendelman
Journal:  Nanomedicine (Lond)       Date:  2011-03-21       Impact factor: 5.307

5.  Where Is the Opioid Use Epidemic in Mexico? A Cautionary Tale for Policymakers South of the US-Mexico Border.

Authors:  David Goodman-Meza; Maria Elena Medina-Mora; Carlos Magis-Rodríguez; Raphael J Landovitz; Steve Shoptaw; Dan Werb
Journal:  Am J Public Health       Date:  2018-11-29       Impact factor: 9.308

6.  Expanding substance use treatment options for HIV prevention with buprenorphine-naloxone: HIV Prevention Trials Network 058.

Authors:  David S Metzger; Deborah Donnell; David D Celentano; J Brooks Jackson; Yiming Shao; Apinun Aramrattana; Liu Wei; Liping Fu; Jun Ma; Gregory M Lucas; Marek Chawarski; Yuhua Ruan; Paul Richardson; Katherine Shin; Ray Y Chen; Jeremy Sugarman; Bonnie J Dye; Scott M Rose; Geetha Beauchamp; David N Burns
Journal:  J Acquir Immune Defic Syndr       Date:  2015-04-15       Impact factor: 3.731

7.  Evaluating network-level predictors of behavior change among injection networks enrolled in the HPTN 037 randomized controlled trial.

Authors:  Laramie R Smith; Steffanie A Strathdee; David Metzger; Carl Latkin
Journal:  Drug Alcohol Depend       Date:  2017-04-05       Impact factor: 4.492

8.  Neighborhood of residence and risk of initiation into injection drug use among street-involved youth in a Canadian setting.

Authors:  Goldis Chami; Dan Werb; Cindy Feng; Kora DeBeck; Thomas Kerr; Evan Wood
Journal:  Drug Alcohol Depend       Date:  2013-04-12       Impact factor: 4.492

Review 9.  Behavioral and biomedical combination strategies for HIV prevention.

Authors:  Linda-Gail Bekker; Chris Beyrer; Thomas C Quinn
Journal:  Cold Spring Harb Perspect Med       Date:  2012-08-01       Impact factor: 6.915

10.  Organised crime and the efforts to combat it: a concern for public health.

Authors:  Lucy Reynolds; Martin McKee
Journal:  Global Health       Date:  2010-11-15       Impact factor: 4.185

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.